Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1888 1
1916 1
1940 1
1945 1
1946 1
1947 1
1948 1
1949 1
1950 3
1951 5
1952 9
1953 3
1954 4
1955 1
1956 11
1957 2
1958 3
1959 1
1960 5
1961 5
1962 9
1963 7
1964 8
1965 14
1966 7
1967 9
1968 15
1969 11
1970 11
1971 8
1972 9
1973 14
1974 11
1975 15
1976 8
1977 22
1978 15
1979 18
1980 9
1981 13
1982 14
1983 14
1984 14
1985 20
1986 19
1987 18
1988 23
1989 22
1990 20
1991 19
1992 27
1993 23
1994 33
1995 35
1996 26
1997 36
1998 36
1999 42
2000 58
2001 54
2002 52
2003 58
2004 96
2005 89
2006 112
2007 152
2008 163
2009 198
2010 171
2011 209
2012 232
2013 244
2014 246
2015 286
2016 271
2017 275
2018 268
2019 312
2020 399
2021 453
2022 427
2023 413
2024 442
2025 393

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,112 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. Among authors: basu s. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.
Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallón de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M. Baruch EN, et al. Among authors: basu s. Nature. 2025 Oct;646(8084):462-473. doi: 10.1038/s41586-025-09370-8. Epub 2025 Aug 20. Nature. 2025. PMID: 40836096 Free PMC article.
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Usmani SZ, et al. Among authors: basu s. Nat Med. 2025 Apr;31(4):1195-1202. doi: 10.1038/s41591-024-03485-7. Epub 2025 Feb 5. Nat Med. 2025. PMID: 39910273 Free PMC article. Clinical Trial.
TFOS DEWS III: Management and Therapy.
Jones L, Craig JP, Markoulli M, Karpecki P, Akpek EK, Basu S, Bitton E, Chen W, Dhaliwal DK, Dogru M, Gomes JAP, Koehler M, Mehta JS, Perez VL, Stapleton F, Sullivan DA, Tauber J, Tong L, Travé-Huarte S, Wolffsohn JS; TFOS Collaborator Group. Jones L, et al. Among authors: basu s. Am J Ophthalmol. 2025 Nov;279:289-386. doi: 10.1016/j.ajo.2025.05.039. Epub 2025 Jun 2. Am J Ophthalmol. 2025. PMID: 40467022 Free article. Review.
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Facon T, et al. Among authors: basu s. Leukemia. 2025 Apr;39(4):942-950. doi: 10.1038/s41375-024-02505-2. Epub 2025 Feb 27. Leukemia. 2025. PMID: 40016302 Free PMC article. Clinical Trial.
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.
Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, Couturier C, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D; GBM TeamLab; Puduvalli VK, Huse J, Beroukhim R, Kim BYS, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Chiocca EA, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Yu KKH, et al. Among authors: basu s. Nat Commun. 2025 Apr 28;16(1):3957. doi: 10.1038/s41467-025-58452-8. Nat Commun. 2025. PMID: 40295505 Free PMC article.
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Moreau P, et al. Among authors: basu s. Leukemia. 2025 Mar;39(3):710-719. doi: 10.1038/s41375-024-02506-1. Epub 2025 Jan 15. Leukemia. 2025. PMID: 39815052 Clinical Trial.
Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial.
Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, Ellis A, Williams J, Cicarelli J, Lam Q, Furmanak T, Schmitt C, Hadi-Nezhad F, Thompson D, Miller C, Little C, Chang D, Basu S. Volkov J, et al. Among authors: basu s. Mol Ther. 2024 Nov 6;32(11):3821-3828. doi: 10.1016/j.ymthe.2024.09.009. Epub 2024 Sep 7. Mol Ther. 2024. PMID: 39245937 Free PMC article. Clinical Trial.
6,112 results